Colorado is currently home to 1805 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD
NCT06496542
Recruiting
The proposed research is a pilot study assessing kidney oxidative metabolism and insulin sensitivity after a 2-year weight loss intervention in those with autosomal dominant polycystic kidney disease who are overweight or obese.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/03/2024
Locations: University of Colorado- Anschutz Medical Campus, Aurora, Colorado
Conditions: Autosomal Dominant Polycystic Kidney
Register for Updates
Evaluating a New Gonadotoxic Risk Stratification System
NCT05052632
Recruiting
The primary objective of this study is to assess if there is an association between a newly described gonadotoxic risk stratification system and post-treatment ovarian reserve as determined by FSH and AMH.
Gender:
FEMALE
Ages:
Between 8 years and 39 years
Trial Updated:
07/03/2024
Locations: University of Colorado, Denver, Colorado
Conditions: Cancer
Register for Updates
Shingrix in Renal Transplant Recipients
NCT04128189
Recruiting
This study evaluates the safety and immune response of the Shingrix vaccine in kidney transplant recipients. Participants on the waiting list for kidney transplant will be given the standard 2 doses of Shingrix. Those participants who have been transplanted by 16 months, may be given a 3rd dose of Shingrix.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/03/2024
Locations: University of Colorado Anschutz, Aurora, Colorado
Conditions: Kidney Transplant Recipient Response to Shingrix Vaccine
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
NCT05948865
Recruiting
The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A) * To assess the safety and tolerability of CPO301 at the dose determined to be safe and tolerable in Part A in patients with Non-Small Cell Lung Cancer... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: Sarah Cannon Research Institute (SCRI) at HealthONE, Denver, Colorado
Conditions: Cancer, Cancer, Lung
Register for Updates
Pathophysiology of Circadian Rhythm Delayed Sleep Wake Phase Disorder
NCT06471374
Recruiting
The goal of this study is to understand factors that contribute to delayed sleep wake phase disorder (DSWPD). The investigators will examine whether patients with DSWPD exhibit alterations in circadian rhythms and sensitivity to light compared to healthy controls. The investigators will also test a new method of predicting circadian rhythms form a blood sample.
Gender:
ALL
Ages:
Between 16 years and 30 years
Trial Updated:
06/26/2024
Locations: University of Colorado, Boulder, Colorado
Conditions: Delayed Sleep Phase Syndrome, Delayed Sleep Phase
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Rocky Mountain Cancer Centers, Aurora, Colorado
Conditions: Breast Cancer
Register for Updates
Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients
NCT05064098
Recruiting
This study will assess how patients' long-term quality of life after different surgical approaches compares to their predicted quality of life.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
06/24/2024
Locations: University of Colorado Hopspital, Aurora, Colorado
Conditions: Breast Cancer
Register for Updates
FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer
NCT05077800
Recruiting
The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease. The names of the study drugs involved in this study are: * 9-ING-41 * Losartan * Ferumoxytol * FOLFIRINOX (made up of 4 different drugs): * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Univesity of Colorado, Aurora, Colorado
Conditions: Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
Register for Updates
Cardiometabolic Consequences of the Loss of Ovarian Function
NCT06264882
Recruiting
The menopause transition is associated with a decrease in artery health and an increased risk for weight gain in storing fat in the stomach area which may increase the risk for heart disease. The purpose of this research is to study how the decrease in estrogen at menopause changes artery health and fat gain, and risk of disease in women as they age. The first aim in this study will determine whether short term and long term low estrogen levels in premenopausal women decreases artery function an... Read More
Gender:
FEMALE
Ages:
Between 20 years and 45 years
Trial Updated:
06/18/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Menopause, Estrogen Deficiency, Aging, Adiposity
Register for Updates
Intervention to Collect and Utilize Sexual Orientation and Gender Identity (SOGI) Information in Hospice
NCT05877391
Recruiting
Older sexual and gender minority (SGM) patients are at risk for receiving inequitable end-of-life care; those with Alzheimer's disease and related dementias (ADRD) are at particularly high risk. Failure to collect and integrate sexual orientation and gender identity (SOGI) data to identify patients' informal support systems may have adverse health consequences for SGM older adults, particularly for those dependent on informal caregivers to provide in-home support and assist with activities of da... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University of Colorado, Aurora, Colorado
Conditions: Sexual and Gender Minorities, Hospice, Alzheimer's Disease and Related Dementias
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Aurora, Colorado
Conditions: Neoplasms
Register for Updates